FDA Approval of Tislelizumab - RATIONALE 305 and 306 in Upper GI Cancers

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Anwaar Saeed, Chief of GI Medical Oncology at UPMC, to discuss the recent approval of Tislelizumab, a new checkpoint inhibitor for upper GI malignancies, including esophageal squamous cell cancer, GE junction, and gastric cancer.We dive deep into the studies that led to Tislelizumab’s approval, including the Rationale 302, 305, and 306 trials. Dr. Saeed explains the unique mechanism of action of Tislelizumab, its higher binding affinity to PD-1, and how it compares to other PD-1 inhibitors like nivolumab and pembrolizumab.Key topics covered in this episode:•⁠  ⁠Overview of Tislelizumab and its mechanism of action•⁠  ⁠Insights from the Rationale 306 trial and its implications for frontline treatment•⁠  ⁠Discussion on the Rationale 305 trial focusing on adenocarcinoma•⁠  ⁠The importance of PD-L1 testing and biomarker-driven treatment decisions•⁠  ⁠Side effect profiles of Tislelizumab compared to other immunotherapies•⁠  ⁠Future directions in the use of immunotherapy for upper GI malignanciesJoin us for this informative discussion that highlights the evolving landscape of cancer treatment and the importance of precision oncology. If you find this episode helpful, please share it with your colleagues and leave us a review!YouTube: https://youtu.be/hQeLdpSzGCkFollow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/Don't forget to subscribe for more practice-changing discussions in the world of oncology. We are the Oncology Brothers!